Literature DB >> 32683750

A male infant with COVID-19 in the context of ARPC1B deficiency.

Lina Maria Castano-Jaramillo1, Marco Antonio Yamazaki-Nakashimada1, Selma Cecilia Scheffler Mendoza1, Juan Carlos Bustamante-Ogando2, Sara Elva Espinosa-Padilla2, Saul O Lugo Reyes2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32683750      PMCID: PMC7405203          DOI: 10.1111/pai.13322

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   5.464


× No keyword cloud information.
To the Editor, The current pandemic of the novel SARS‐CoV‐2 infection has affected over 10 million humans around the planet. The clinical manifestations of coronavirus disease 2019 (COVID‐19) are diverse, ranging from asymptomatic or mild flu‐like symptoms to atypical pneumonia, severe respiratory distress syndrome, systemic inflammation, immune dysregulation, and coagulopathy. Inborn errors of immunity (IEI) are a heterogeneous group of more than 430 rare congenital disorders with increased susceptibility to infection, autoimmunity, atopy, hyperinflammation, and cancer. Autosomal recessive ARPC1B deficiency is an actinopathy, as are DOCK8 deficiency and the Wiskott‐Aldrich syndrome. Defective actin polymerization affects hematopoietic cells, impairing their migration and immunological synapse , which results in a combined immune deficiency characterized by leukocytosis, eosinophilia, platelet abnormalities, and hypergammaglobulinemia, and clinically, by eczema and food allergy; infections caused by bacteria, fungi, and viruses; vasculitis; and bleeding diathesis . Here, we describe a male infant patient with known ARPC1B deficiency, who was hospitalized for COVID‐19 pneumonia and improved without requiring intensive care or mechanical ventilation. Informed consent through protocols approved by the institutional review boards of the National Institute of Pediatrics was obtained from the patient’s family. An 8‐month‐old male infant was brought to the emergency department with high‐grade fever. His family history is remarkable for one brother who died as a newborn from intracranial bleeding and an 11‐year‐old sister with the same genetic defect and decreased proliferative response to mitogens, who underwent hematopoietic stem cell transplantation twice without success, and is currently on antimycobacterial treatment, antimicrobial prophylaxis, and regular subcutaneous immunoglobulin. The patient was first seen at age 1 month for eczema and rectal bleeding attributed to cow milk protein allergy. At age 4 months, he developed bronchiolitis caused by respiratory syncytial virus (RSV) and oral candidiasis. Laboratory workup revealed leukocytosis (17 500‐33 600/mm3), eosinophilia (5600‐20 100/mm3), and a marginally high platelet count (467 000) with normal platelet volume, as well as high serum IgG (737 mg/dL) and IgA (165 mg/dL), with normal IgM (37.7 mg/dL). Lymphocyte subsets showed slightly low CD3+ (2.315 cells), normal CD4+ (23%, 1974), and low CD8+ (3%, 257 cells). B cells and NK cells were elevated at 48% (4116 cells) and 15% (1286 cells), respectively. Whole exome sequencing identified a homozygous 46‐base pair deletion in exon 8 of ARPC1B (chr7: 99,392,784 hg38; p.Glu300fs). Upon his arrival to the emergency department, he was febrile with tachycardia and signs of septic shock, requiring rapid fluid resuscitation. He showed no respiratory or gastrointestinal signs, although he also had a post‐traumatic ulcerated lesion under the tongue with dark discoloration, which raised a concern for fungal infection. Intravenous antibiotics (ciprofloxacin) with antifungal coverage were started within the first hour and a dose of intravenous immunoglobulin (IVIG) at 1 g/kg. Blood counts revealed leukocytosis, neutrophilia, and mild eosinophilia without lymphopenia, while platelets were initially found within normal limits. A day later, blood culture had grown Pseudomonas aeruginosa. During his second day of hospitalization, the patient persisted febrile, tachycardic, and tachypneic, with oxygen desaturation into the low 80s. Chest X‐ray showed non‐specific bilateral interstitial opacities in the perihilar regions (Figure 1). Real‐time polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2, an oral swab taken upon admission, came back positive, and he was then transferred to a COVID‐19 isolation area. There was no known contact with another positive COVID‐19 case.
FIGURE 1

Bilateral interstitial infiltrates with perihilar predominance

Bilateral interstitial infiltrates with perihilar predominance The potassium hydroxide (KOH) test for oral thrush was negative for yeast cells, after which amphotericin was switched to fluconazole. Supplemental oxygen was discontinued on day 6 of hospitalization, when mild thrombocytopenia and a prolonged thromboplastin time (aPTT) (but normal fibrinogen and ferritin serum levels) were reported (see Table 1). After completing 14 days of antimicrobial treatment, the patient was discharged without ever requiring intensive care unit admission or mechanical ventilation. Specific serum antibodies to SARS‐CoV‐2 were assessed 8 weeks after the positive RT‐PCR test and came back negative.
TABLE 1

Blood counts and acute‐phase reactants on admission and on day 5

Hospital admission (day 0)Day 5 of hospital admission
Hb10.4 mg/dL12.9 mg/dL
Leukocytes40 300 cells/μL9800 cells/μL
Neutrophils30 100 cells/μL3800 cells/μL
Lymphocytes5400 cells/μL2400 cells/μL
Eosinophils600 cells/μL2000 cells/μL
Platelets165 000109 000
C‐reactive proteinNot availableNot available
D‐dimerNot availableNot available
FibrinogenNot available265 mg/dL
TriglyceridesNot available219 mg/dL
FerritinNot available268 ng/mL
Blood counts and acute‐phase reactants on admission and on day 5 The behavior of COVID‐19 in patients with IEI might help dissect the immune response to SARS‐CoV‐2. A few cases of adults with COVID‐19 and predominantly antibody deficiencies have been reported , ; some of them developed acute respiratory distress syndrome (ARDS), while some had a milder course of illness. Based on what we know, innate immune defects in genes involved in type 1 interferon response (such as IRF7, IRF9, TLR3) are the most likely candidates to result in severe disease and death in patients with flu‐like virus infection . In a few cases of fatal influenza A (H1N1), variants in genes associated with familial hemophagocytic lymphohistiocytosis (FHL) and a decreased cytolytic function of NK cells were also reported . Our patient was on monthly supplemental IVIG treatment, and he received an additional dose during his hospital stay. This, and his young age, might have ameliorated the clinical course . He had a favorable evolution, despite the known susceptibility to viral infection and immune dysregulation in ARPC1B‐deficient patients . There were no signs of severe infection, ARDS, and hyperinflammation or of “cytokine storm” unleashed by SARS‐CoV‐2. Despite him having a combined immune deficiency, our patient fully recovered without the need of additional supportive measures other than IVIG, supplemental oxygen, and antibiotic treatment directed against the documented bacteremia. Although pediatric cases of COVID‐19 are fewer compared to adults, some severe presentations and deaths among children have been reported. The presence of a restricted repertoire of IgG (since infants have no previous exposure to coronaviruses) might play a role in the better outcome seen in pediatric patients. Antibody‐dependent enhancement has been implicated in the development of severe COVID‐19 in the elderly . Additionally, lung cells from children and women show a lower expression of membrane‐bound ACE‐2, which may also be protective against severe pneumonia. Conceivably, some immune defects could protect patients with certain IEIs from mounting a full uncontrolled inflammatory response against SARS‐CoV‐2 . The cytoskeleton is a regulator of gene transcription, coupling cell mechanics with the activity of NF‐κB. RNA betacoronaviruses are thought to alter the cytoskeleton architecture to facilitate viral replication and output . Thus, ARPC1B deficiency and other actinopathies might limit SARS‐CoV‐2 replication. Furthermore, Th2 cytokines modulate ACE2 (angiotensin‐converting enzyme 2) and TMPRSS2 expression in airway epithelial cells , and children with allergies (asthma and/or allergic rhinitis) have a lower expression of ACE2 . Patients with ARPC1B deficiency often have allergic diseases; their Th2‐biased response could help explain the milder presentation seen in our patient. Insights from protective mechanisms in children, with and without certain immune defects, could facilitate the identification of therapeutic targets.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Lina Maria Castano‐Jaramillo: Data curation (equal); investigation (equal); writing‐original draft (lead); writing‐review and editing (equal). Marco Antonio Yamazaki‐Nakashimada: Investigation (equal); supervision (equal); writing‐review and editing (equal). Selma Cecilia Scheffler Mendoza: Data curation (equal); supervision (equal); writing‐review and editing (equal). Juan Carlos Bustamante‐Ogando: Writing‐review and editing (equal). Sara Elva Espinosa‐Padilla: Supervision (supporting); validation (supporting); visualization (supporting); writing‐review and editing (supporting). Saul O. Lugo Reyes: Conceptualization (lead); supervision (lead); writing‐original draft (lead); writing‐review and editing (equal).

ETHICAL APPROVAL

The patient and his family gave written informed consent for the diagnostic procedures and for publication of the case report.

Peer Review

The peer review history for this article is available at https://publons.com/publon/10.1111/pai.13322.
  12 in total

1.  Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza.

Authors:  Grant S Schulert; Mingce Zhang; Ndate Fall; Ammar Husami; Diane Kissell; Andrew Hanosh; Kejian Zhang; Kristina Davis; Jeffrey M Jentzen; Lena Napolitano; Javed Siddiqui; Lauren B Smith; Paul W Harms; Alexei A Grom; Randy Q Cron
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

2.  Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency.

Authors:  Taco W Kuijpers; Anton T J Tool; Ivo van der Bijl; Martin de Boer; Michel van Houdt; Iris M de Cuyper; Dirk Roos; Floris van Alphen; Karin van Leeuwen; Emma L Cambridge; Mark J Arends; Gordon Dougan; Simon Clare; Ramiro Ramirez-Solis; Steven T Pals; David J Adams; Alexander B Meijer; Timo K van den Berg
Journal:  J Allergy Clin Immunol       Date:  2016-12-10       Impact factor: 10.793

3.  Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.

Authors:  Hiroki Kimura; Dave Francisco; Michelle Conway; Fernando D Martinez; Donata Vercelli; Francesca Polverino; Dean Billheimer; Monica Kraft
Journal:  J Allergy Clin Immunol       Date:  2020-05-15       Impact factor: 10.793

4.  A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.

Authors:  Jean-Laurent Casanova; Helen C Su
Journal:  Cell       Date:  2020-05-13       Impact factor: 41.582

5.  The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019.

Authors:  Lauren Fill; Lauren Hadney; Kelsey Graven; Roberta Persaud; Robert Hostoffer
Journal:  Ann Allergy Asthma Immunol       Date:  2020-05-05       Impact factor: 6.347

6.  Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin.

Authors:  Rana Aljaberi; Kholoud Wishah
Journal:  Ann Allergy Asthma Immunol       Date:  2020-06-04       Impact factor: 6.347

Review 7.  The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures.

Authors:  Paolo Maria Matricardi; Roberto Walter Dal Negro; Roberto Nisini
Journal:  Pediatr Allergy Immunol       Date:  2020-06-05       Impact factor: 5.464

8.  Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.

Authors:  Annarosa Soresina; Daniele Moratto; Marco Chiarini; Ciro Paolillo; Giulia Baresi; Emanuele Focà; Michela Bezzi; Barbara Baronio; Mauro Giacomelli; Raffaele Badolato
Journal:  Pediatr Allergy Immunol       Date:  2020-05-19       Impact factor: 5.464

9.  Mechano-genomic regulation of coronaviruses and its interplay with ageing.

Authors:  Caroline Uhler; G V Shivashankar
Journal:  Nat Rev Mol Cell Biol       Date:  2020-05       Impact factor: 94.444

10.  Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.

Authors:  Daniel J Jackson; William W Busse; Leonard B Bacharier; Meyer Kattan; George T O'Connor; Robert A Wood; Cynthia M Visness; Stephen R Durham; David Larson; Stephane Esnault; Carole Ober; Peter J Gergen; Patrice Becker; Alkis Togias; James E Gern; Mathew C Altman
Journal:  J Allergy Clin Immunol       Date:  2020-04-22       Impact factor: 10.793

View more
  7 in total

1.  Hematopoietic Stem Cell Transplantation in ARPC1B Deficiency.

Authors:  Stefano Giardino; Stefano Volpi; Federica Lucioni; Roberta Caorsi; Jennifer Schneiderman; Abigail Lang; Amer Khojah; Taco Kuijpers; Ionanna Papadatou; Anna Paisiou; Laura Alonso; Ansgar Schulz; Nufar Marcus; Marco Gattorno; Maura Faraci
Journal:  J Clin Immunol       Date:  2022-06-29       Impact factor: 8.317

2.  SARS-CoV-2 associated with death in an infant with congenital chylothorax.

Authors:  Handan Bezirganoglu; Nilufer Okur
Journal:  J Paediatr Child Health       Date:  2021-05-18       Impact factor: 1.929

3.  Risk factors for bronchiolitis and asthma, and COVID-19 symptoms in young children.

Authors:  Philippe Eigenmann
Journal:  Pediatr Allergy Immunol       Date:  2021-02       Impact factor: 6.377

4.  Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.

Authors:  Samaneh Delavari; Hassan Abolhassani; Farhad Abolnezhadian; Fateme Babaha; Sara Iranparast; Hamid Ahanchian; Nasrin Moazzen; Mohammad Nabavi; Saba Arshi; Morteza Fallahpour; Mohammad Hassan Bemanian; Sima Shokri; Tooba Momen; Mahnaz Sadeghi-Shabestari; Rasol Molatefi; Afshin Shirkani; Ahmad Vosughimotlagh; Molood Safarirad; Meisam Sharifzadeh; Salar Pashangzadeh; Fereshte Salami; Paniz Shirmast; Arezou Rezaei; Tannaz Moeini Shad; Minoo Mohraz; Nima Rezaei; Lennart Hammarström; Reza Yazdani; Asghar Aghamohamamdi
Journal:  J Clin Immunol       Date:  2020-12-01       Impact factor: 8.317

Review 5.  Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19.

Authors:  Caspar I van der Made; Mihai G Netea; Frank L van der Veerdonk; Alexander Hoischen
Journal:  Genome Med       Date:  2022-08-19       Impact factor: 15.266

Review 6.  COVID-19 and Inborn Errors of Immunity.

Authors:  Ottavia M Delmonte; Riccardo Castagnoli; Luigi D Notarangelo
Journal:  Physiology (Bethesda)       Date:  2022-08-09

7.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study.

Authors:  Isabelle Meyts; Giorgia Bucciol; Isabella Quinti; Bénédicte Neven; Alain Fischer; Elena Seoane; Eduardo Lopez-Granados; Carla Gianelli; Angel Robles-Marhuenda; Pierre-Yves Jeandel; Catherine Paillard; Vijay G Sankaran; Yesim Yilmaz Demirdag; Vassilios Lougaris; Alessandro Aiuti; Alessandro Plebani; Cinzia Milito; Virgil Ash Dalm; Kissy Guevara-Hoyer; Silvia Sánchez-Ramón; Liliana Bezrodnik; Federica Barzaghi; Luis Ignacio Gonzalez-Granado; Grant R Hayman; Gulbu Uzel; Leonardo Oliveira Mendonça; Carlo Agostini; Giuseppe Spadaro; Raffaele Badolato; Annarosa Soresina; François Vermeulen; Cedric Bosteels; Bart N Lambrecht; Michael Keller; Peter J Mustillo; Roshini S Abraham; Sudhir Gupta; Ahmet Ozen; Elif Karakoc-Aydiner; Safa Baris; Alexandra F Freeman; Marco Yamazaki-Nakashimada; Selma Scheffler-Mendoza; Sara Espinosa-Padilla; Andrew R Gennery; Stephen Jolles; Yazmin Espinosa; M Cecilia Poli; Claire Fieschi; Fabian Hauck; Charlotte Cunningham-Rundles; Nizar Mahlaoui; Klaus Warnatz; Kathleen E Sullivan; Stuart G Tangye
Journal:  J Allergy Clin Immunol       Date:  2020-09-24       Impact factor: 10.793

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.